Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

Read the release.

Advertisements